Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis
Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis
Exploratory study of anti-pneumococcal immune response in patients with Anti-neutrophil
 cytoplasmic antibody (ANCA)-associated vasculitis (AAV) immunized according to new vaccine
 recommendations (i.e. with a combined vaccine schedule (13-valent conjugate pneumococcal
 vaccine -PCV13- followed by a 23-valent non-conjugate pneumococcal vaccine -PPV23- 8 weeks
 later).
The purpose of this study is to determine whether this vaccination schedule induces
 sufficient protective immunity (serotype-specific enzyme linked immunosorbent assay (ELISA)
 and opsonophagocytosis (OPA) response rates) in AAV-patients receiving immunosuppressive
 therapy.
Inclusion Criteria:

 -  Age ≥ 18 years

 -  ANCA-associated vasculitis: diagnosis of granulomatosis with polyangiitis, microscopic
 polyangiitis or eosinophilic granulomatosis with polyangiitis according to American
 College of Rheumatology criteria

 -  Indication for pneumococcal vaccination according to French recommendations (statement
 of the Haut Conseil de Santé Publique regarding pneumococcal vaccination for adults
 and children older than 2 years old at risk for invasive pneumococcal disease, April
 25Th 2013)

 Exclusion Criteria:

 -  History of pneumococcal immunization 36 months to 24hours before VO.

 -  Patients with known, or suspected pregnancy

 -  Patients planning to get pregnant in the year following inclusion

 -  Splenectomy

 -  Eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss) flare

 -  Infection during the week before inclusion

 -  Patient without social security coverage

 -  Individuals opposal